Antibody-Drug Conjugates Are ‘Changing Outcomes’ in HR+ HER2– Breast Cancer


Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Sara M. Tolaney, MD, MPH, spoke with CancerNetwork® about how findings from the phase 3 TROPiCS-02 study (NCT03901339) highlight the ability of sacituzumab govitecan-hziy (Trodelvy) to improve patient outcomes over chemotherapy among those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, discussed the low response rates and short duration of disease control associated with single agent chemotherapy in the aforementioned population.

In the TROPiCs-02 study, investigators reported a median overall survival (OS) of 14.5 months with sacituzumab vs 11.2 months with chemotherapy of physician’s choice (Hazard ratio, 0.79; 95% CI, 0.65-0.95; P = .0133).Additionally, the 12-month, 18-month, and 24-month OS rates among patients receiving sacituzumab vs those receiving chemotherapy were 60.9% (95% CI, 54.8%-66.4%) vs47.1% (95% CI, 41.0%-53.0%), 39.2% (95% CI, 33.4%-45.0%) vs 31.7% (95% CI, 26.2%-37.4%), and 25.6% (95% CI, 20.4%-31.2%) vs 21.1% (95% CI, 16.3%-26.3%), respectively.


It's really exciting to see that antibody-drug conjugates are changing outcomes for patients. We've been so used to seeing single agent chemotherapy being given sequentially in this pretreated setting, and, unfortunately, it has been associated with low response rates and short duration of disease control.

These data looking at sacituzumab can tell us that we do have new agents that do better than standard chemotherapy and are really improving outcomes for our patients.


Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Related Content